menu
    • menu
    [{"orgOrder":0,"company":"Rion","sponsor":"ProPharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Pooled Platelet Concentrate","moa":"Platelet level","graph1":"Undisclosed","graph2":"Phase I","graph3":"Rion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rion \/ ProPharma","highestDevelopmentStatusID":"6","companyTruncated":"Rion \/ ProPharma"},{"orgOrder":0,"company":"Rion","sponsor":"Rion","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Extracellular Vesicles","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Rion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Catheter","sponsorNew":"Rion \/ Rion","highestDevelopmentStatusID":"6","companyTruncated":"Rion \/ Rion"},{"orgOrder":0,"company":"Rion","sponsor":"Professional Education and Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Pep Purified Exosome Product","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Rion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Rion \/ Professional Education and Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Rion \/ Professional Education and Research Institute"},{"orgOrder":0,"company":"Rion","sponsor":"Henry M. Jackson Foundation | Walter Reed National Military Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Pep Purified Exosome Product","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Rion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rion \/ Henry M. Jackson Foundation | Walter Reed National Military Medical Center","highestDevelopmentStatusID":"7","companyTruncated":"Rion \/ Henry M. Jackson Foundation | Walter Reed National Military Medical Center"},{"orgOrder":0,"company":"Rion","sponsor":"Caidya CRO","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Purified Exosome Product","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Rion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rion \/ Caidya CRO","highestDevelopmentStatusID":"6","companyTruncated":"Rion \/ Caidya CRO"},{"orgOrder":0,"company":"Rion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Purified Exosome Product","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Rion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rion \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Rion \/ Undisclosed"},{"orgOrder":0,"company":"Rion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Purified Exosome Product","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Rion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rion \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Rion \/ Undisclosed"},{"orgOrder":0,"company":"Rion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Purified Exosome Product","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Rion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Rion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rion \/ Undisclosed"},{"orgOrder":0,"company":"Rion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Rion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rion \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Rion

    Menu

    Rion

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Rion

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Rion

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Purified Exosome Product

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            RION Enrolls First Patient in Phase 1b Trial of PEP for Knee Osteoarthritis

                            Details : RION's Purified Exosome Product (PEP) is a shelf stable product in a lyophilized powder derived from human platelets that contains stabilized platelet-derived regenerative exosomes.

                            Product Name : PEP

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            March 11, 2025

                            Lead Product(s) : Purified Exosome Product

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Rion

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Rion

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pep Purified Exosome Product

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I/ Phase II

                            Sponsor : Henry M. Jackson Foundation | Walter Reed National Military Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate the Safety, Tolerability, and Efficacy of PEP-TISSEEL in Subjects With Chronic Radiation Ulc...

                            Details : Pep Purified Exosome Product is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 27, 2025

                            Lead Product(s) : Pep Purified Exosome Product

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Henry M. Jackson Foundation | Walter Reed National Military Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Rion

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Rion

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Purified Exosome Product

                            Therapeutic Area : Podiatry

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            RION Completes Enrollment for Phase 2 Diabetic Foot Ulcer Trial with PEP™

                            Details : PEP is a proprietary, lyophilized exosome-based powder derived from human platelets, engineered to enhance the body’s natural healing mechanisms, currently being investigated for diabetic foot ulcers.

                            Product Name : PEP

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            January 13, 2025

                            Lead Product(s) : Purified Exosome Product

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Rion

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Rion

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Purified Exosome Product

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            RION Initiates Phase 1b Study of Purified Exosome Product™ for Knee Osteoarthritis

                            Details : RION's Purified Exosome Product (PEP) is a shelf stable product in a lyophilized powder derived from human platelets that contains stabilized platelet-derived regenerative exosomes.

                            Product Name : PEP

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            September 10, 2024

                            Lead Product(s) : Purified Exosome Product

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Rion

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Rion

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Purified Exosome Product

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I

                            Sponsor : Caidya CRO

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 1b Clinical Trial to Evaluate PEP and EUFLEXXA for Knee Osteoarthritis (KOA)

                            Details : Purified Exosome Product is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Osteoarthritis, Knee.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            June 17, 2024

                            Lead Product(s) : Purified Exosome Product

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I

                            Sponsor : Caidya CRO

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Rion

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Rion

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Podiatry

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ventus Initiates Clinical Testing of VENT-03, an Orally Administered cGAS Inhibitor

                            Details : Purified Exosome Product, designed to promote cell growth and formation of new blood vessels, while also reducing inflammation and protecting cells, is being investigated for diabetic foot ulcer.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 07, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Rion

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Rion

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pep Purified Exosome Product

                            Therapeutic Area : Podiatry

                            Study Phase : Phase II

                            Sponsor : Professional Education and Research Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 2a Multi-Center Prospective, Randomized Trial to Evaluate the Safety & Efficacy of Topical PEP-TISSEEL f...

                            Details : Pep Purified Exosome Product is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetic Foot.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 20, 2024

                            Lead Product(s) : Pep Purified Exosome Product

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase II

                            Sponsor : Professional Education and Research Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Rion

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Rion

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pooled Platelet Concentrate

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : ProPharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PEP on a Skin Graft Donor Site Wound

                            Details : Pooled Platelet Concentrate is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            December 11, 2020

                            Lead Product(s) : Pooled Platelet Concentrate

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : ProPharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Rion

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Rion

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Extracellular Vesicles

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Christopher J. McLeod

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety Evaluation of Intracoronary Infusion of Extracellular Vesicles in Patients Following Coronary Stent Imp...

                            Details : Extracellular Vesicles is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 31, 2020

                            Lead Product(s) : Extracellular Vesicles

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Christopher J. McLeod

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth